Brief information on dabigatran
- Dabigatran (pradaxa) is an oral direct thrombin inhibitor.
- Approved for
thromboprophylaxis
after elective hip or knee replacement surgery, prevention of stroke in
nonvalvular
atrial fibrillation
- Oral administration
- Prophylactic dose is 220 mg orally once daily for venous thromboembolism and 300 mg
orally once daily for stroke prevention.
- No coagulation
monitoring necessary
- A specific antidote (idarucizumab, Praxbind) against dabigatran is available and
can be given in emergency cases of acute bleeding.
- Elimination half-life of dabigatran is 13–18 hours,
up to 28 hours in patients with severe renal impairment (contraindication).